Serum 15-d-PGJ2 and PPARγ levels are reduced in manic episode of bipolar disorder while IL-4 levels are not affected

References

• Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005;293:2528–2530. doi: 10.1001/jama.293.20.2528
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Forgione R, Maccari M, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013;148:161–169. doi: 10.1016/j.jad.2013.02.001
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Kakar R, Berk M, et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord. 2016;18:89–101. doi: 10.1111/bdi.12373
   PubMed Web of Science ®Google Scholar
• Kalelioğlu T, Genç A, Karamustafalıoğlu N, et al. Bipolar disorder and inflammation. J Mood Disord. 2017;7:54–64.
   Web of Science ®Google Scholar
• Baumeister D, Russell A, Pariante CM, et al. Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors. Soc Psychiatry Psychiatr Epidemiol. 2014;49:841–849. doi: 10.1007/s00127-014-0887-z
   PubMed Web of Science ®Google Scholar
• Modabbernia A, Taslimi S, Brietzke E, et al. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74:15–25. doi: 10.1016/j.biopsych.2013.01.007
   PubMed Web of Science ®Google Scholar
• Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144:16–27. doi: 10.1016/j.jad.2012.06.010
   PubMed Web of Science ®Google Scholar
• Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol. 2006;1(S1):147.
   Google Scholar
• Sommer IE, Begemann M, Kahn RS. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012;73:414–419. doi: 10.4088/JCP.10r06823
   PubMed Web of Science ®Google Scholar
• Meyer U, Schwarz MJ, Müller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther. 2011;132:96–110. doi: 10.1016/j.pharmthera.2011.06.003
   PubMed Web of Science ®Google Scholar
• Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav. 2011;35:804–817. doi: 10.1016/j.neubiorev.2010.10.001
   PubMed Web of Science ®Google Scholar
• Kim YK, Jung HG, Myint AM, et al. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104:91–95. doi: 10.1016/j.jad.2007.02.018
   PubMed Web of Science ®Google Scholar
• Maes M, Bosmans E, Calabrese J, et al. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 1995;29:141–152. doi: 10.1016/0022-3956(94)00049-W
   PubMed Web of Science ®Google Scholar
• Maes M, Meltzer HY, Bosmans E, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord. 1995;34:301–309. doi: 10.1016/0165-0327(95)00028-L
   PubMed Web of Science ®Google Scholar
• Maes M, Delange J, Ranjan R, et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997;66:1–11. doi: 10.1016/S0165-1781(96)02915-0
   PubMed Web of Science ®Google Scholar
• Wadee AA, Kuschke RH, Wood LA, et al. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol. 2002;17:175–179. doi: 10.1002/hup.390
   PubMed Web of Science ®Google Scholar
• Heneka MT, Landreth GE. PPARs in the brain. Biochim Biophys Acta. 2007;1771:1031–1045. doi: 10.1016/j.bbalip.2007.04.016
   PubMed Web of Science ®Google Scholar
• Martínez-Gras I, Pérez-Nievas BG, García-Bueno B, et al. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr Res. 2011;128:15–22. doi: 10.1016/j.schres.2011.01.018
   PubMed Web of Science ®Google Scholar
• Ferret-Sena V, Maia E Silva A, Sena A, et al. Natalizumab treatment modulates peroxisome proliferator-activated receptors expression in women with multiple sclerosis. PPAR Res. 2016;2016:1–5. doi: 10.1155/2016/5716415
   Web of Science ®Google Scholar
• Kapadia R, Yi J-H, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci. 2008;13:1813–1826. doi: 10.2741/2802
   PubMed Web of Science ®Google Scholar
• Gervois P, Fruchart J-C, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab. 2007;3:145–156. doi: 10.1038/ncpendmet0397
   PubMedGoogle Scholar
• Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. 2008;454:470–477. doi: 10.1038/nature07202
   PubMed Web of Science ®Google Scholar
• Galea E, Heneka MT, Dello Russo C, et al. Intrinsic regulation of brain inflammatory responses. Cell Mol Neurobiol. 2003;23:625–635. doi: 10.1023/A:1025084415833
   Web of Science ®Google Scholar
• García-Bueno B, Madrigal JLM, Lizasoain I, et al. Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol Psychiatry. 2005;57:885–894. doi: 10.1016/j.biopsych.2005.01.007
   PubMed Web of Science ®Google Scholar
• Feinstein DL. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther. 2003;5:67–73. doi: 10.1089/152091503763816481
   PubMedGoogle Scholar
• García-Bueno B, Bioque M, Mac-Dowell KS, et al. Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull. 2014;40:376–387. doi: 10.1093/schbul/sbt001
   PubMed Web of Science ®Google Scholar
• Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol. 2011;14:997–1012. doi: 10.1017/S1461145710001410
   PubMed Web of Science ®Google Scholar
• Ando T, Ishikawa T, Kawamura N, et al. Analysis of tumor necrosis factor-α gene promoter polymorphisms in anorexia nervosa. Psychiatr Genet. 2001;11:161–164. doi: 10.1097/00041444-200109000-00009
   PubMed Web of Science ®Google Scholar
• Barbosa IG, Bauer ME, Machado-Vieira R, et al. Cytokines in bipolar disorder: paving the way for neuroprogression. Neural Plast. 2014;2014:1–9. doi: 10.1155/2014/360481
   Web of Science ®Google Scholar
• Guloksuz S, Cetin EA, Cetin T, et al. Cytokine levels in euthymic bipolar patients. J Affect Disord. 2010;126:458–462. doi: 10.1016/j.jad.2010.04.027
   PubMed Web of Science ®Google Scholar
• Association AP. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington, DC: American Psychiatric Pub; 2013.
   Google Scholar
• Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45:742–747. doi: 10.1001/archpsyc.1988.01800320058007
   PubMed Web of Science ®Google Scholar
• Akdemir A, Türkçapar MH, Orsel SD, et al. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry. 2001;42:161–165. doi: 10.1053/comp.2001.19756
   PubMed Web of Science ®Google Scholar
• Karadağ F, Oral T, Yalçin FA, et al. Reliability and validity of Turkish translation of Young Mania Rating Scale. Turk Psikiyatr Derg. 2002;13:107–114.
   PubMedGoogle Scholar
• García-Álvarez L, Caso JR, García-Portilla MP, et al. Regulation of inflammatory pathways in schizophrenia: a comparative study with bipolar disorder and healthy controls. Eur Psychiatry. 2018;1:47–50.
   Google Scholar
• Ribeiro-Santos A, Lucio TA, Salgado JV. Evidence for an immune role on cognition in schizophrenia: a systematic review. Curr Neuropharmacol. 2014;12:273–280. doi: 10.2174/1570159X1203140511160832
   PubMed Web of Science ®Google Scholar
• Thompson Ray M, Weickert CS, Wyatt E, et al. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci. 2011;36:195–203. doi: 10.1503/jpn.100048
   PubMed Web of Science ®Google Scholar
• Drexhage RC, Knijff EM, Padmos RC, et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother. 2010;10:59–76. doi: 10.1586/ern.09.144
   PubMed Web of Science ®Google Scholar
• Arabzadeh S, Ameli N, Zeinoddini A, et al. Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. Bipolar Disord. 2015;17:606–614. doi: 10.1111/bdi.12324
   PubMed Web of Science ®Google Scholar
• Park EY, Cho IJ, Kim SG. Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. Cancer Res. 2004;64:3701–3713. doi: 10.1158/0008-5472.CAN-03-3924
   PubMed Web of Science ®Google Scholar
• Colle R, de Larminat D, Rotenberg S, et al. PPAR-γ agonists for the treatment of major depression: a review. Pharmacopsychiatry. 2017;50:49–55.
   Web of Science ®Google Scholar
• Chappuis B, Braun M, Stettler C, et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev. 2007;23:392–399. doi: 10.1002/dmrr.715
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547–1554. doi: 10.2337/diacare.28.7.1547
   PubMed Web of Science ®Google Scholar
• Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest. 2004;27:982–991. doi: 10.1007/BF03347546
   Web of Science ®Google Scholar
• Carrizo E, Fernández V, Quintero J, et al. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Res. 2008;103:83–93. doi: 10.1016/j.schres.2008.03.004
   PubMed Web of Science ®Google Scholar
• Fan X, Pristach C, Liu EY, et al. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007;149:267–271. doi: 10.1016/j.psychres.2006.07.011
   PubMed Web of Science ®Google Scholar
• Pou KM, Massaro JM, Hoffmann U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation. 2007;116:1234–1241. doi: 10.1161/CIRCULATIONAHA.107.710509
   PubMed Web of Science ®Google Scholar
• Derosa G, Sahebkar A, Maffioli P. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. J Cell Physiol. 2018;233:153–161. doi: 10.1002/jcp.25804
   Web of Science ®Google Scholar
• Lv X, Zhang L, Sun J, et al. Interaction between peroxisome proliferator-activated receptor gamma polymorphism and obesity on type 2 diabetes in a Chinese Han population. Diabetol Metab Syndr. 2017;9:7. doi: 10.1186/s13098-017-0205-5
   Web of Science ®Google Scholar
• Kauer-Sant’Anna M, Kapczinski F, Andreazza AC, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009;12:447–458. doi: 10.1017/S1461145708009310
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Scully P, Scott LV, et al. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90:263–267. doi: 10.1016/j.jad.2005.11.015
   PubMed Web of Science ®Google Scholar
• Mota R, Gazal M, Acosta BA, et al. Interleukin-1β is associated with depressive episode in major depression but not in bipolar disorder. J Psychiatr Res. 2013;47:2011–2014. doi: 10.1016/j.jpsychires.2013.08.020
   PubMed Web of Science ®Google Scholar
• Doganavsargil-Baysal O, Cinemre B, Aksoy UM, et al. Levels of TNF-α, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum Psychopharmacol. 2013;28:160–167. doi: 10.1002/hup.2301
   PubMed Web of Science ®Google Scholar
• Hope S, Dieset I, Agartz I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res. 2011;45:1608–1616. doi: 10.1016/j.jpsychires.2011.08.003
   PubMed Web of Science ®Google Scholar
• Moldoveanu AI, Shephard RJ, Shek PN. The cytokine response to physical activity and training. Sports Med. 2001;31:115–144. doi: 10.2165/00007256-200131020-00004
   PubMed Web of Science ®Google Scholar
• Patel SR, Zhu X, Storfer-Isser A, et al. Sleep duration and biomarkers of inflammation. Sleep. 2009;32:200–204. doi: 10.1093/sleep/32.2.200
   PubMed Web of Science ®Google Scholar